You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
报道指当局下令销毁强生6,000剂於问题工厂生产的新型肺炎疫苗
阿思达克 06-12 10:55
外电报道,美国药品及食品管理局(FDA)下令强生(JNJ.US)销毁数百万剂新型肺疫苗,由於相关疫苗於巴尔的摩的问题工厂生产,另外有两个批次、为数数百万剂疫苗仍能使用,其余仍有数批在审视中。

《路透》引述消息人士指,获准使用的疫苗共1,000万剂。另外《纽约时报》早前亦引述消息指,当局下令销毁疫苗达6,000万剂。

报道指,相关巴尔的摩工厂已於4月遭FDA禁止生产新型肺炎疫苗,强生亦将因於相关工厂生产疫苗遭罚。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account